文献速递主动脉疾病

单中心经验:经皮血管内主动脉瘤修复术中单把Perclose联合Angio-Seal VIP 8F的择期杂交技术与标准双把Perclose的比较

Single-Center Experience on the Elective Hybrid Combination of Single Perclose + Angio-Seal VIP 8F Compared With Standard Dual Perclose During Percutaneous Endovascular Aortic Aneurysm Repair.
PubMed 文献 · J Endovasc Ther · 2024-07-31

该单中心研究纳入2022年11月至2023年11月接受择期经皮血管内主动脉瘤修复术、股动脉入路健康且鞘管外径≤20F的连续患者,采用抛硬币随机分组比较单把Perclose联合单把Angio-Seal VIP 8F的杂交技术与标准双把Perclose技术。结果显示杂交技术组即刻止血率100% vs 双把Perclose组87.5%(p=0.006),中位费用330欧元 vs 384欧元(p<0.001),技术成功率均为100%,无外科转开放。作者认为在选定患者中杂交技术不劣于标准双把Perclose。

要点

  • 杂交技术组即刻止血率100%,双把Perclose组87.5%(p=0.006)。
  • 双把Perclose入路(OR=35.6)和肥胖(OR=19.7)为即刻止血失败的独立危险因素。
  • 杂交技术中位费用330欧元,低于双把Perclose的384欧元(p<0.001)。

核心结论

  • 在选定患者中,择期经皮血管内主动脉瘤修复术采用单把Perclose联合单把Angio-Seal VIP 8F的杂交技术似乎不劣于标准双把Perclose技术。
  • 杂交技术在减少即刻止血失败和费用方面呈现积极趋势,两种技术均实现技术成功并避免外科入路转开放。

研究设计与样本

  • 单中心研究,纳入2022年11月至2023年11月接受择期经皮血管内主动脉瘤修复术、股动脉入路健康且鞘管外径≤20F的连续患者。
  • 采用抛硬币随机化决定使用单把Perclose联合单把Angio-Seal VIP 8F的杂交技术或标准双把Perclose技术。
  • 共60例患者,中位年龄78岁(四分位距72-85岁),14例(24%)仅研究1侧股动脉入路,共106个入路。

主要发现

  • 杂交技术组58个入路(54.7%),双把Perclose组48个入路(45.3%),两组术前特征和鞘管直径(杂交技术16F vs 双把Perclose 18F;p=0.202)均衡。
  • 即刻止血率杂交技术组100% vs 双把Perclose组87.5%(p=0.006)。
  • 双把Perclose组6例股动脉出血均通过血管内追加器械解决,无外科入路转开放,技术成功率100%。
  • 杂交技术组中位费用330欧元(四分位距=0) vs 双把Perclose组384欧元(四分位距360-456欧元)(p<0.001)。
  • 30天死亡率为3%(2例虚弱患者),无入路相关并发症;中位随访134天(四分位距41-227天),杂交技术组1例(2%)股动脉小假性动脉瘤在62天后经凝血酶注射成功治疗。

关键数值与推荐

  • 多因素分析显示双把Perclose入路(OR=35.6;95%CI 18.3-36.8;p<0.001)和肥胖(OR=19.7;95%CI 1.4-23.9.5;p<0.001)为即刻止血失败的独立危险因素。

临床怎么用

  • 作者认为在选定患者中,择期经皮血管内主动脉瘤修复术采用单把Perclose联合单把Angio-Seal VIP 8F的杂交技术似乎不劣于标准双把Perclose技术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This single-center study aimed to assess patients who underwent intentional percutaneous endovascular aortic aneurysm repair (pEVAR) with Hybrid Technique combining a single Perclose (Abbott, Abbott Park, Illinois) Suture-Mediated Closure Device + single Angio-Seal VIP 8F (Terumo, Tokyo, Japan) and compare outcomes with the standard Dual Perclose technique. MATERIALS AND METHODS: Consecutive elective pEVAR patients treated from November 2022 to November 2023, with healthy femoral accesses and introducer sheaths ≤20 French (F) outer diameter, were included. Coin-toss randomization determined whether a combination of single Perclose Device + single Angio-Seal VIP 8F (Hybrid Technique) or the standard double Perclose Devices (Dual Perclose) was used. In Hybrid Technique, a single Perclose device was positioned at 12 o'clock; a single Angio-Seal VIP 8F was placed after sheaths removal. Dual Perclose followed standard procedure. Primary endpoints included immediate hemostasis, sheath diameter differences, access conversion rate, technical success, and cost analysis. RESULTS: The study involved 60 pEVAR patients (median age=78, interquartile range [IQR]=72-85 years) within the inclusion criteria. In 14 (24%) cases, only 1 femoral access was studied. There were 106 pEVAR accesses, with 58 (54.7%) in the Hybrid Technique group and 48 (45.3%) in the Dual Perclose group. Both groups exhibited homogeneity in pre-operative characteristics and sheath diameter (Hybrid Technique-16F vs Dual Perclose-18F; p=0.202). Immediate hemostasis was achieved in 100% of the Hybrid Technique group vs 87.5% for the Dual Perclose group (p=0.006). Surgical access conversion was unnecessary. Technical success was 100%, with all 6 femoral bleeding cases after Dual Perclose resolved endovascularly, using additional devices. Cost analysis showed a median cost of 330 euros (IQR=0) for the Hybrid Technique group vs 384 euros (IQR=360-456) for the Dual Perclose group (p<0.001). Thirty-day mortality was 3%, in 2 fragile patients, without access-related complications. Multivariate analysis identified Dual Perclose access (odds ratio [OR]=35.6; 95% confidence interval [CI]=18.3-36.8; p<0.001) and obesity (OR=19.7; 95% CI=1.4-23.9.5; p<0.001) as independent risk factors for immediate hemostasis failure. Median follow-up was 134 days (IQR=41-227), with 1 Hybrid Technique case (2%) successfully treated with thrombin injection for a small femoral pseudoaneurysm after 62 days. CONCLUSIONS: The elective Hybrid Technique with combination of single Perclose Device + single Angio-Seal VIP 8F during pEVAR in selected patients appears to be non-inferior to the standard Dual Perclose procedure. It demonstrates a positive trend in reducing immediate hemostasis failure and costs. Both procedures achieved technical success and avoiding surgical access conversions.Clinical ImpactThis study introduces a novel elective hybrid technique combining a single Perclose device with a single Angio-Seal VIP 8Fr for percutaneous endovascular abdominal aortic interventions. Results for hybrid technique showed 100% technical success and efficient immediate hemostasis, while costing less than standard dual Perclose procedure. Both procedures did not require surgical conversions. Despite being a single-center study, it demonstrates potential benefits of the intentional application of this hybrid technique towards minimally invasiveness. Obesity and dual Perclose technique were identified as independent risk factors for hemostasis failure, reaffirming the hybrid technique procedure's efficacy as well as and non-inferiority to standard procedure.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Spath P, Maioli F, Campana F, et al. Single-Center Experience on the Elective Hybrid Combination of Single Perclose + Angio-Seal VIP 8F Compared With Standard Dual Perclose During Percutaneous Endovascular Aortic Aneurysm Repair. J Endovasc Ther. 2024. PMID: 39082670. doi:10.1177/15266028241266182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。